Nifedipine Pediatric Dose — Cardiovascular Hypertension
Nifedipine is a dihydropyridine calcium channel blocker that reduces systemic vascular resistance through selective arterial smooth muscle relaxation. It is used in pediatric patients for the acute and short-term management of hypertension, including hypertensive urgency in monitored settings. Its relatively rapid onset following oral or enteral administration makes it a practical option when intravenous access is unavailable or not required.
Pediatric Dosing
The recommended dose of nifedipine is 0.25–0.5 mg/kg/dose administered orally (PO) or via nasogastric/nasoduodenal tube (NG/ND) every 4–6 hours as needed (PRN). The maximum single dose is 10 mg.
- Dose range: 0.25 mg/kg/dose (lower end) to 0.5 mg/kg/dose (upper end)
- Frequency: every 4–6 hours PRN
- Route: PO or NG/ND
- Maximum per dose: 10 mg
Worked example: For a 20 kg child using 0.25 mg/kg/dose: 20 × 0.25 = 5 mg per dose. At 0.5 mg/kg/dose: 20 × 0.5 = 10 mg per dose (which is also the maximum). For a 30 kg child, the weight-based upper limit would exceed 10 mg, so the dose should be capped at 10 mg per dose regardless of weight.
Indications and Clinical Context
Nifedipine is indicated in pediatric patients for the management of acute hypertension or hypertensive urgency where oral or enteral therapy is appropriate. It may be used in inpatient, PICU, or emergency department settings when blood pressure reduction is needed but the clinical picture does not mandate intravenous antihypertensive therapy. Common underlying etiologies in children include renal parenchymal disease, renovascular hypertension, and medication-related hypertension.
As a PRN agent, nifedipine is generally reserved for symptomatic or significantly elevated blood pressure readings confirmed on serial measurement. Clinicians should evaluate for end-organ involvement and consult institutional or nephrology-specific hypertension protocols to guide escalation of therapy.
Administration and Monitoring
Nifedipine immediate-release capsules or liquid formulations may be administered orally or via NG/ND tube. The liquid contents of capsules are sometimes used for enteral dosing in younger children; consult pharmacy for appropriate formulation and concentration. Blood pressure should be monitored closely following each dose, with assessment for excessive hypotension, reflex tachycardia, flushing, and headache.
- Route: PO or NG/ND only per this dosing description; no IV formulation is used for this indication
- Maximum single dose: 10 mg — do not exceed regardless of weight
- Monitor: blood pressure and heart rate at 30–60 minutes post-dose
- Adverse effects: hypotension, reflex tachycardia, peripheral edema, flushing
- Frequency: administer PRN every 4–6 hours; consult institutional protocol for maximum daily dosing and duration
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.